Peptide

A decade ago, medical weight loss revolved around calories, willpower, and a short list of underwhelming prescription options. Peptide therapy has reshaped what's clinically possible — and for many patients, the gap between effort and results is finally narrowing.

Peptides are short chains of amino acids that act as signaling molecules in the body. In weight loss, the most clinically validated peptides target gut-brain hormones that regulate appetite, satiety, and metabolism. GLP-1 (glucagon-like peptide-1) is the headline. Released by the small intestine after a meal, it slows gastric emptying, signals fullness to the brain, suppresses glucagon, and stimulates insulin. Synthetic GLP-1 analogs amplify and prolong those effects.

The current FDA-approved options for chronic weight management include semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) — the last being a dual GLP-1/GIP agonist that produces roughly 15–21% mean weight loss over 72 weeks in clinical trials. Behind them in the pipeline, retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon receptors — has shown about 24% mean weight loss in Phase 2 data, with Phase 3 results emerging in 2026.

What patients should understand: these medications act on the digestive system as much as the brain. Side effects — nausea, reflux, delayed gastric emptying, and occasionally gallbladder issues — are common, predictable, and usually manageable with proper dose titration and a structured nutrition plan alongside the medication.

The bigger point is this: peptide therapy is not a shortcut. It's a clinical tool that works best with medical oversight, individualized nutrition, and attention to muscle preservation. Used well, it changes what's achievable. Used carelessly, it produces side effects without sustainable results.